Search This Blog

Wednesday, June 17, 2015

Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study (NYSE:LLY)

INDIANAPOLIS, June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.



Lilly's investigational medicine for prevention of migraine met primary endpoint in a Phase 2b study (NYSE:LLY)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)